FDA Clearance Tracker · P160030-S017
FreeStyle Libre 14 Day Flash Glucose Monitoring System
Last checked: Nov 20, 2026Latest source record: Jul 23, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Jul 23, 2018
Approved
Time to decision
104 days
Received Apr 10, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P160030-S017
- Device name
- FreeStyle Libre 14 Day Flash Glucose Monitoring System
- Applicant
- Abbott Diabetes Care, Inc.
- Applicant location
- Alameda, CA
- Received
- Apr 10, 2018
- Decided
- Jul 23, 2018
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P160030
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the FreeStyle Libre 14 Day Flash Glucose Monitoring System. The FreeStyle Libre 14 Day Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device indicated for the management of diabetes in persons age 18 and older. It is designed to replace blood glucose testing for diabetes treatment decisions. The System detects trends and tracks patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. Interpretation of the System readings should be based on the glucose trends and several sequential readings over time. The System is intended for single patient use and requires a prescription.
Source documents
Other decisions for Abbott Diabetes Care, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K233537 · Decided Apr 23, 2024 · 172 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.